Dhaliwal, Amritpal https://orcid.org/0000-0001-5919-6456
Williams, Felicity R.
Quinlan, Jonathan I.
Allen, Sophie L.
Greig, Carolyn
Filer, Andrew
Raza, Karim
Ghosh, Subrata
Lavery, Gareth G.
Newsome, Philip N.
Choudhary, Surabhi
Breen, Leigh
Armstrong, Matthew J.
Elsharkawy, Ahmed M.
Lord, Janet M.
Funding for this research was provided by:
National Institute for Health Research
Article History
Received: 18 March 2021
Accepted: 19 November 2021
First Online: 11 December 2021
Declarations
:
: The Health Research Authority and West Midlands Solihull Research Ethics Service Committee Authority (REC reference: 18/WM/0167) approved this study. All participants will provide informed written consent. Potential subjects will be identified by the relevant clinical team and by the lead researcher as detailed in patient selection. This will include a face to face discussion, confirmation of the study details via letter or email, and a follow-up telephone call. All patients will be provided with a patient information sheet (PIS) outlining the purpose of the study. They will receive a follow-up telephone call/consultation, within 4 weeks after receiving the PIS, where an investigator will introduce and explain the study participation. Formal written consent will be taken at the first visit. The patient will have opportunities to further discuss their participation at their initial visit. The patient will be free to refuse to take part or withdraw from the study at any time and this decision will not affect their care. A copy of the informed consent form will be offered to the patient, and the original placed in the case report file and uploaded on to the hospital electronic patient record.
: Not applicable.
: The authors declare they have no competing interests.